Legal & Regulatory

Chemours Faces Securities Class Action Over Opteon Demand Claims

CCThe Chemours Company

The Chemours Company and several senior executives have been sued in a securities class action that alleges investors were misled about demand for the company's Opteon refrigerant products, according to announcements from multiple law firms representing shareholders. The suit covers people who bought Chemours securities between February 20, 2026 and August 4, 2026, and investors have until December 7, 2026 to apply for the lead plaintiff role.

The case was filed in the United States District Court for the District of Delaware and docketed as 26-cv-01299, seeking remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. The company's chief executive and chief financial officer are named as individual defendants, and the claims follow an 18.63% decline in the stock that the firms link to the alleged overstatement of refrigerant aftermarket demand.

Chemours reported revenue of 5.81 billion USD in fiscal 2025 along with a net loss of 386.0 million USD and diluted earnings per share of -2.56 USD. Its next earnings release is scheduled for February 18, 2027.

Important questions to consider

The class period runs from February 20, 2026 through August 4, 2026, inclusive. Investors seeking the lead plaintiff role must file applications by December 7, 2026, according to the firms announcing the case.

Sources

This summary was written with AI from the headlines and excerpts of the sources above and figures from the Intrinsic Alpha database. It is not investment advice.